A Longitudinal Study of the Association of Opioid Use with Change in Pain Interference and Functional Limitations in a Nationally Representative Cohort of Adults with Osteoarthritis in the United States
Tóm tắt
Real-world data are sparse on longitudinal associations of opioid use with pain interference with activities (PIA) and daily function with osteoarthritis (OA) in the USA. Data from the 2010–2015 Medical Expenditure Panel Surveys were analyzed for community-dwelling adults with OA. Opioid use patterns were defined as persistent, intermittent, and no use. Evaluated outcomes were a change in PIA and functional limitations (activities of daily living [ADL], instrumental ADL [IADL], social and work activities, and cognitive function). Multivariable regression analyses explored the association of persistent/intermittent versus no opioid use with PIA and functional limitations. Results were weighted for the US population. Among 4172 patients (66.2% female, 80.8% white, mean age 61.7 years), 62.1% reported no PIA change at follow-up, 17.9% worsened, and 20.0% improved. Although 51.0–93.1% of patients reported no functional limitations, 3.8–13.1% worsened (1.1–11.3% improved). Relative to no opioid use, persistent users had higher odds of severe/extreme PIA (adjusted odds ratio [AOR], 2.91; 95% confidence interval [CI], 1.95–4.32; P < 0.001) and moderate PIA (AOR, 2.04; 95% CI, 1.31–3.20; P < 0.01) at follow-up. For patients with baseline functional limitations, persistent opioid users were more likely to report physical and work limitations at follow-up (both P < 0.05). For patients without baseline functional limitations, persistent opioid users had higher odds than those without use of reporting IADL, physical, social, and cognitive limitations at follow-up (all P < 0.05); intermittent users were more likely to report physical and social limitations (both P < 0.05). Persistent opioid use for pain in patients with OA appeared to be associated with poorer PIA and functional outcomes, regardless of baseline functional status. These findings highlight the importance of patient-reported outcomes for opioid benefit–risk assessment and suggest the need for alternative analgesic approaches.
Tài liệu tham khảo
Smith E, Hoy DG, Cross M, et al. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(8):1462–9.
Cisternas MG, Murphy L, Sacks JJ, et al. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. Arthritis Care Res (Hoboken). 2016;68(5):574–80.
Park J, Mendy A, Vieira ER. Various types of arthritis in the United States: prevalence and age-related trends from 1999 to 2014. Am J Public Health. 2018;108(2):256–8.
Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthr Cartil. 2013;21(9):1145–53.
daCosta DiBonaventura M, Gupta S, McDonald M, Sadosky A. Evaluating the health and economic impact of osteoarthritis pain in the workforce: results from the National Health and Wellness Survey. BMC Musculoskelet Disord. 2011;12:83.
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16(2):137–62.
Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–74.
McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22(3):363–88.
Berger A, Bozic K, Stacey B, et al. Patterns of pharmacotherapy and health care utilization and costs prior to total hip or total knee replacement in patients with osteoarthritis. Arthritis Rheum. 2011;63(8):2268–75.
Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract. 2012;12(7):550–60.
Wright EA, Katz JN, Abrams S, Solomon DH, Losina E. Trends in prescription of opioids from 2003–2009 in persons with knee osteoarthritis. Arthritis Care Res (Hoboken). 2014;66(10):1489–95.
DeMik DE, Bedard NA, Dowdle SB, et al. Are we still prescribing opioids for osteoarthritis? J Arthroplasty. 2017;32(12):3578–82.
Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624–45.
Shah D, Zhao X, Gandhi K, et al. Opioid use, pain interference with activities, and their associated burden in a nationally representative sample of adults with osteoarthritis in the United States (US): results of a retrospective, cross-sectional analysis [abstract 276]. Pain Med. 2018;19(4):893.
Zhao X, Shah D, Gandhi K, et al. The association of pain interference and opioid use with healthcare utilization and costs, and wage loss among adults with osteoarthritis in the United States. J Med Econ. 2019;22(11):1192–201.
Cohen JW, Cohen SB, Banthin JS. The Medical Expenditure Panel Survey: a national information resource to support healthcare cost research and inform policy and practice. Med Care. 2009;47(7 Suppl 1):S44–50.
Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey (MEPS): survey background. 2009. https://meps.ahrq.gov/about_meps/survey_back.jsp. Accessed 12 Dec 2018.
Ware JE Jr, Kosinski M, Turner-Bowker D, et al. User’s manual for the SF-12v2 health survey. 2nd ed. Lincoln, RI: QualityMetric; 2009.
Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9.
Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10:20–30.
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.
Myers AM. The clinical Swiss army knife. Empirical evidence on the validity of IADL functional status measures. Med Care. 1992;30(5 Suppl):MS96–111.
Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10.
da Costa BR, Nüesch E, Kasteler R, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2014;(9):CD003115.
Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018;319(9):872–82.
Webster LR. Opioid-induced constipation. Pain Med. 2015;16(Suppl 1):S16–21.
Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27(5):417–33.
Gore M, Tai KS, Sadosky A, et al. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis. J Med Econ. 2011;14(4):497–507.
Sharma L, Cahue S, Song J, et al. Physical functioning over three years in knee osteoarthritis: role of psychosocial, local mechanical, and neuromuscular factors. Arthritis Rheum. 2003;48(12):3359–70.
Mallen CD, Peat G, Thomas E, Lacey R, Croft P. Predicting poor functional outcome in community-dwelling older adults with knee pain: prognostic value of generic indicators. Ann Rheum Dis. 2007;66(11):1456–61.
van Dijk GM, Veenhof C, Spreeuwenberg P, et al. Prognosis of limitations in activities in osteoarthritis of the hip or knee: a 3-year cohort study. Arch Phys Med Rehabil. 2010;91(1):58–66.
Hayes CJ, Payakachat N, Li C. Evaluation of opioid use among patients with back disorders and arthritis. Qual Life Res. 2018;27(11):3021–35.
Hayes CJ, Li X, Li C, et al. Health-related quality of life among chronic opioid users, nonchronic opioid users, and nonopioid users with chronic noncancer pain. Health Serv Res. 2018;53(5):3329–49.
Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 2017;152(6):e170504.